Oncternal Therapeutics Inc

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Oncternal Therapeutics Inc reports Q1 loss but advances promising therapies

Oncternal Therapeutics Inc's Q1 2024 performance reflects ongoing investment in innovative therapies amidst a net loss of $8.4 million.
The company's financial stability, upcoming milestones, and engagement with analysts position it well for future growth and development.
Challenges in managing expenses, meeting clinical data timelines, and ensuring therapeutic success underscore the need for strategic decision-making and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2021 financial results after the U.S. financial markets close on Thursday, November 4, 2021. Oncternal's management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a comprehensive business update and discuss the Company's financial results.

Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results

Oncternal Therapeutics (ONCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Oncternal Therapeutics (ONCT) Report Negative Q3 Earnings? What You Should Know

Big Pharma has validated ROR1 therapies which are at the core of ONCT's oncology program. Despite initial enthusiasm for ONCT, the market no longer assigns any premium to its stock.

Why I Added Oncternal Therapeutics To My Watchlist

SAN DIEGO, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced pre-clinical data from ONCT-534, an androgen receptor N-terminal-domain-binding small molecule degrader, was accepted for virtual poster presentation at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics on October 7-10, 2021. Oncternal has conducted a series of preclinical studies in collaboration with the Center for Cancer Research at the University of Tennessee Health Science Center.

Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted for Virtual Poster Presentation at AACR-NCI-EORTC Virtual International Conference on Molecular Targets 

SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted inducement awards to Emily Samec, who joined the Company as Vice President, Operations and Project Management, and 3 new non-executive employees.

Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the following conferences in the month of September:

Oncternal Therapeutics to Participate in September Investor Conferences

SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Steven Hamburger, Ph.D. as Senior Vice President of Regulatory Affairs and Quality Assurance.

Oncternal Therapeutics Rounds Out Leadership Team with Appointment of Steven Hamburger, Ph.D. as Senior Vice President, Regulatory Affairs and Quality Assurance

Oncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q2 2021 Results - Earnings Call Transcript

Shares of Oncternal Therapeutics (NASDAQ:ONCT) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 52.94% over the past year to ($0.16), which missed the estimate of ($0.14).

Recap: Oncternal Therapeutics Q2 Earnings

SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today reported financial results for the second quarter of 2021. Oncternal management will host a webcast today at 5:00 p.m. ET to provide a business update and discuss its second quarter of 2021 financial results.

Oncternal Provides Business Update and Announces Second Quarter 2021 Financial Results

SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the BTIG Virtual Biotechnology Conference being held August 9-10, 2021.

Oncternal Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

Will Oncternal Therapeutics (ONCT) Report Negative Q2 Earnings? What You Should Know

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2021 financial results after the U.S. financial markets close on Thursday, August 5, 2021. Oncternal's management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a comprehensive business update and discuss the Company's financial results.

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results

SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Pablo Urbaneja as Senior Vice President, Corporate Development.

Oncternal Therapeutics Appoints Pablo Urbaneja as Sr. Vice President, Corporate Development

Oncternal is a small biotech player with two major assets: Cirmtuzumab and TK216. Recent data updates have solidified Oncternal's approach in Mantle Cell Lymphoma and Ewing Sarcoma.

Oncternal Therapeutics: New Data Continues To Derisk

SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 10:30 am Eastern Time.

Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference

Oncternal Therapeutics Inc (NASDAQ: ONCT) has announced updated interim clinical data from its ongoing Phase 1/2 trial evaluating TK216 in relapsed or refractory Ewing sarcoma, or soft-tissue sarcoma. Data will be presented at the American Society of Clinical Oncology 2021 Annual Meeting.

Oncternal Shares Jump After Encouraging Early Action In Soft-Tissue Sarcoma Trial With TK216

The stock price of Oncternal Therapeutics Inc (NASDAQ: ONCT) increased by over 9% pre-market. This is why it happened.

Oncternal Therapeutics (ONCT) Stock: Over 9% Increase Pre-Market Explanation

SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from the oral presentation on its ongoing Phase 1/2 clinical trial evaluating TK216, an investigational, potentially first-in-class, targeted small-molecule inhibitor of the E26 transformation-specific (ETS) family of oncoproteins, in patients with relapsed or refractory Ewing sarcoma, to be presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.

Oncternal Therapeutics Presents Updated Interim Data for TK216 in Patients with Relapsed or Refractory Ewing Sarcoma in an Oral Session at ASCO 2021

SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data, from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial, that will be presented in poster form at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.  In the CIRLL study, cirmtuzumab, an investigational anti-ROR1 monoclonal antibody, is being evaluated in combination with ibrutinib in patients with MCL and CLL. The clinical trial is being conducted in collaboration with UC San Diego School of Medicine and is partially funded by the California Institute for Regenerative Medicine.

Oncternal Therapeutics Presents Updated Interim Data for Cirmtuzumab in Combination with Ibrutinib at ASCO 2021

SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of industry veteran Salim Yazji, M.D., as Chief Medical Officer.

Oncternal Therapeutics Announces Appointment of Salim Yazji as Chief Medical Officer

Oncternal Therapeutics, Inc. (ONCT) CEO Jim Breitmeyer on Q1 2021 Results - Earnings Call Transcript

Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of -20.00% and -32.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Oncternal Therapeutics (ONCT) Reports Q1 Loss, Misses Revenue Estimates

SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today reported financial results for the first quarter of 2021. Oncternal management will host a webcast today at 5:00 p.m. ET to discuss its first quarter of 2021 financial results and to provide a business update.

Oncternal Provides Business Update and Announces First Quarter 2021 Financial Results

SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2021 financial results after the U.S. financial markets close on Thursday, May 6, 2021. Oncternal's management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the Company's financial results and provide a comprehensive business update.

News for Oncternal Therapeutics Inc Stock (ONCT)